Please use this identifier to cite or link to this item: http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/2454
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPARDESHI, KUNDANSINGH A.en_US
dc.contributor.authorKUMAR, T. ANANDen_US
dc.contributor.authorRAVIKUMAR, GOVINDANen_US
dc.contributor.authorShukla, Manjulikaen_US
dc.contributor.authorKaul, Graceen_US
dc.contributor.authorChopra, Sidharthen_US
dc.contributor.authorCHAKRAPANI, HARINATHen_US
dc.date.accessioned2019-04-25T07:00:12Z
dc.date.available2019-04-25T07:00:12Z
dc.date.issued2019-01en_US
dc.identifier.citationBioconjugate Chemistry, 30(3), 751-759.en_US
dc.identifier.issn1043-1802en_US
dc.identifier.urihttp://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/2454-
dc.identifier.urihttps://doi.org/10.1021/acs.bioconjchem.8b00887en_US
dc.description.abstractFluoroquinolones (FQs) are among the front-line antibiotics used to treat severe infections caused by Gram-negative bacteria. However, recently, due to toxicity concerns, their use has been severely restricted. Hence, efforts to direct delivery of this antibiotic specifically to bacteria/site of infection are underway. Here, we report a strategy that uses a bacterial enzyme for activation of a prodrug to generate the active antibiotic. The ciprofloxacin-latent fluorophore conjugate 1, which is designed as a substrate for nitroreductase (NTR), a bacterial enzyme, was synthesized. Upon activation by NTR, release of Ciprofloxacin (CIP) as well as a fluorescence reporter was observed. We provide evidence for the prodrug permeating bacteria to generate a fluorescent signal and we found no evidence for activation in mammalian cells supporting selectivity of activation within bacteria. As a testament to its efficacy, 1 was found to have potent bactericidal activity nearly identical to CIP and significantly reduced the bacterial burden in a neutropenic mouse thigh infection model, again, at comparable potency with CIP, a clinically used FQ. Thus, together, we have developed a small molecule that facilitates bacteria-specific fluoroquinolone delivery.en_US
dc.language.isoenen_US
dc.publisherAmerican Chemical Societyen_US
dc.subjectCephalosporin 3-Quinolone Estersen_US
dc.subjectDual-Action Cephalosporinsen_US
dc.subjectControlled-Releaseen_US
dc.subjectEscherichia-Colien_US
dc.subjectSulfur-Dioxideen_US
dc.subjectProdrugen_US
dc.subjectFluoroquinolonesen_US
dc.subjectDerivativesen_US
dc.subjectDesignen_US
dc.subjectAntibioticsen_US
dc.subjectTOC-APR-2019en_US
dc.subject2019en_US
dc.titleTargeted Antibacterial Activity Guided by Bacteria-Specific Nitroreductase Catalytic Activation to Produce Ciprofloxacinen_US
dc.typeArticleen_US
dc.contributor.departmentDept. of Chemistryen_US
dc.identifier.sourcetitleBioconjugate Chemistryen_US
dc.publication.originofpublisherForeignen_US
Appears in Collections:JOURNAL ARTICLES

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.